Biomedical Engineering Reference
In-Depth Information
S. No.
Company and
Strategic Alliances
Product Details
Clinical Status as
on Dec. 2009
Drug Target/
Tissue
Indication
Route of
Delivery
Delivery System
5.
Nucleonics
NUC B1000
Phase I
4 HBV genes/
liver
Hepatitis B
antiviral agent
Intravenous
Plasmid DNA
formulated in
cationic lipid
delivery system
6.
TransDerm (Santa
Cruz, CA)
TD101
Phase Ib
Targets the
N171K mutant
form of the
gene/skin
Pachyonychia
congenita
Topical
Two delivery
methods:
1. Soluble tip mi-
croneedle array
2. Topical gene
cream, lipid-
based technology
7.
Calando
Pharmaceuticals
CALAA-01
Phase I
M2 subunit of
ribonucleotide
reductase/solid
tumors
Anticancer
Intravenous
RONDEL (RNAi/
oligonucleotide
nanoparticle
delivery)
8.
MDRNA Inc.
MDR-03030
Preclinical phase
Targets
conserved in
region of the
influenza viral
genome
Acts on
influenza viral
genome; has the
ability to mutate
around the
compound
Intranasal
Combined UsiRNAs
with DiLA2 delivery
platform
9.
Benitec
rHIV7-shl-TAR-
CCR5RZ
Phase I
HIV tat/rev
gene, TAT-
responsive
elements, CCR5
receptors/targets
stem cells
AIDS-related
lymphoma
Systemic
DNA-based plasmid
expressing anti-HIV
RNA
Search WWH ::
Custom Search